Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide.

التفاصيل البيبلوغرافية
العنوان:	Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide.
المؤلفون:	Hopkins AM; Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia., Vitry AI; Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia., O'Doherty CE; Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia., Proudman SM; Department of Rheumatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.; Discipline of Medicine, Adelaide University, Adelaide, South Australia, Australia., Wiese MD; Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
المصدر:	International journal of rheumatic diseases [Int J Rheum Dis] 2017 Nov; Vol. 20 (11), pp. 1795-1797. Date of Electronic Publication: 2015 Jul 14.
نوع المنشور:	Letter
اللغة:	English
بيانات الدورية:	Publisher: Wiley on behalf of the Asia Pacific League of Associations for Rheumatology Country of Publication: England NLM ID: 101474930 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1756-185X (Electronic) Linking ISSN: 17561841 NLM ISO Abbreviation: Int J Rheum Dis Subsets: MEDLINE
أسماء مطبوعة:	Original Publication: [Oxford, UK] : Wiley on behalf of the Asia Pacific League of Associations for Rheumatology
مواضيع طبية MeSH:	Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Biological Products/therapeutic use , Drug Costs/trends , Immunosuppressive Agents/therapeutic use , Leflunomide/therapeutic use , Practice Patterns, Physicians'/*trends, Antirheumatic Agents/economics ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/economics ; Australia ; Biological Products/economics ; Clinical Decision-Making ; Drug Costs/legislation & jurisprudence ; Drug Utilization Review ; Health Expenditures/trends ; Humans ; Immunosuppressive Agents/economics ; Leflunomide/economics ; Practice Patterns, Physicians'/economics ; Practice Patterns, Physicians'/legislation & jurisprudence ; Program Evaluation ; Time Factors ; Treatment Outcome
المشرفين على المادة:	0 (Antirheumatic Agents) 0 (Biological Products) 0 (Immunosuppressive Agents) G162GK9U4W (Leflunomide)
تواريخ الأحداث:	Date Created: 20150716 Date Completed: 20190107 Latest Revision: 20190107
رمز التحديث:	20231215
DOI:	10.1111/1756-185X.12717
PMID:	26176865
قاعدة البيانات:	MEDLINE

View record at Wiley

Full Text Finder

الوصف
تدمد:	1756-185X
DOI:	10.1111/1756-185X.12717